High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia

详细信息    查看全文

• 作者：Antonio R. Lucena-Araujo^a ; Fabio Morato de Oliveira^a ; Sabrina Dias Leite-Cueva^b ; Guilherme Augusto dos Santos^a ; Roberto Passeto Falcao^a ; Eduardo Magalhã ; es Rego^a ; ^{emrego@hcrp.fmrp.usp.br}
• 关键词：Acute myeloid leukemia ; Aurora kinase ; Cytogenetics
• 刊名：Leukemia Research
• 出版年：2011
• 出版时间：February 2011
• 年：2011
• 卷：35
• 期：2
• 页码：260-264
• 全文大小：494 K

文摘

In the present study, we analyzed AURKA and AURKB gene expression in 70 acute myeloid leukemia (AML) patients. There was no difference between leukemic samples and bone marrow mononuclear cells (BMMCs, n = 8) or CD34⁺ progenitors (n = 10) from healthy donors. High white blood cells (WBC) counts were observed in the AURKA⁺ and AURKB⁺ groups, but no significant differences regarding age, gender, platelet counts or frequency of FLT3-ITD mutations. AURKA, but not AURKB, expression was independently associated with high WBC counts (OR: 3.15, 95 % CI 1.07–9.24, p = 0.03). Moreover, the majority of cases that overexpressed AURKA and AURKB presented unfavorable cytogenetic abnormalities (p < 0.001). In conclusion, we described a significant association between overexpression of AURKA/B and cytogenetics findings in AML, which may be relevant to new therapeutic approaches, based on Aurora kinase inhibitors.